AHZ - ADMEDUS LTD
Morgans rates AHZ as Add (1) - The company has signalled a detailed strategic review with the resignation of its managing director. Morgans expects further details to be announced in the near term.
The broker makes no changes to forecasts, although moderate its licensing assumption in the immunotherapies division in FY17. An Add rating is maintained but Morgans acknowledges the under performance of the share price over the past two years is testing investor patience.
At this stage the broker does not rule out a need for additional capital. Target is reduced to $1.48 from $1.69.
Target price is $1.48 Current Price is $0.30 Difference: $1.18
If AHZ meets the Morgans target it will return approximately 393% (excluding dividends, fees and charges). The company's fiscal year ends in June.
How Low Will It Go?, page-18
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.00 |
Change
-0.150(1.48%) |
Mkt cap ! $211.3M | |||
| Open | High | Low | Value | Volume |
| $10.26 | $10.35 | $9.80 | $295.8K | 29.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22 | $9.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.00 | 2758 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |